Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis

被引:10
|
作者
Liu, Zhikun [1 ,2 ]
Ling, Qi [1 ,2 ]
Wang, Jianguo [1 ,2 ]
Xie, Haiyang [1 ,2 ]
Xu, Xiao [1 ,2 ]
Zheng, Shusen [1 ,2 ]
机构
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat,Minist P, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Surg,Div Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China
关键词
annexin A2; hepatocellular carcinoma; liver cirrhosis; liver transplantation; prognosis; ALCOHOLIC LIVER-DISEASE; PROTEOME ANALYSIS; RISK-FACTORS; HEPATITIS-B; CELL; TRANSPLANTATION; FIBRINOLYSIS; CANCER; MICE;
D O I
10.3892/ol.2013.1337
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In China, hepatocellular carcinoma (HCC) usually develops following a long history of chronic hepatitis B infection or cirrhosis. To evaluate the diagnostic role of annexin A2 (ANXA2), a possible tumor marker, in patients with hepatitis B virus (HBV)-related HCC, particularly those with a history of cirrhosis, the present study prospectively enrolled 87 patients with HBV-related HCC (with cirrhosis), 39 patients with HBV-related cirrhosis and 27 healthy controls. The expression levels of serum and tissue ANXA2 were determined using an enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining, respectively. The serum levels of ANXA2 were significantly elevated in the patients with HCC (median, 567.2 mu g/ml; P=0.003) and cirrhosis (median, 414.8 mu g/ml; P=0.011) compared with the healthy controls (median, 241.9 mu g/ml). However, no significant differences were observed in the serum ANXA2 levels between the patients with HCC and those with cirrhosis. The immunohistochemical staining analysis showed that the healthy controls did not show positive staining, while the number of cases immunoreactive for ANXA2 steadily increased from the liver cirrhosis tissues (20/39, 51.3%) to the non-cancer (53/87, 60.9%) and cancer tissues (68/87, 78.2%). The cancer tissues exhibited a significantly higher ANXA2-positive rate compared with the non-cancer (P=0.013) and liver cirrhosis tissues (P=0.002). Furthermore, marked ANXA2 staining was more prevalent in the cancer tissues (16/87, 18.4%) than the non-cancer (4/87, 4.6%; P=0.004) and liver cirrhosis (1/39, 2.6%; P=0.034) tissues. The sensitivity, specificity and diagnostic accuracy of tissue ANXA2 for HCC in cirrhosis were 78.2, 42.1 and 56.8%, respectively. The ANXA2 expression levels in the serum and cancer tissues were not associated with tumor-free survival or patient survival following liver transplantation. Serum or tissue ANXA2 is not a good diagnostic marker for HCC in HBV-related cirrhosis and is not associated with prognosis.
引用
收藏
页码:125 / 129
页数:5
相关论文
共 50 条
  • [1] Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients
    Mohamed K Shaker
    Hanzada I Abdel Fattah
    Ghada S Sabbour
    Iman F Montasser
    Sara M Abdelhakam
    Eman El Hadidy
    Rehab Yousry
    Ahmed K El Dorry
    World Journal of Hepatology, 2017, 9 (09) : 469 - 476
  • [2] Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma
    El-Abd, Nevine
    Fawzy, Amal
    Elbaz, Tamer
    Hamdy, Sherif
    TUMOR BIOLOGY, 2016, 37 (01) : 211 - 216
  • [3] Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma
    Sun, Yulin
    Gao, Guangzhou
    Cai, Jianqiang
    Wang, Youliang
    Qu, Xiuhua
    He, Lidong
    Liu, Fang
    Zhang, Yangjun
    Lin, Kaixuan
    Ma, Shouzhi
    Yang, Xiao
    Qian, Xiaohong
    Zhao, Xiaohang
    CARCINOGENESIS, 2013, 34 (03) : 595 - 604
  • [4] Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma
    Zhang, Hai-Jian
    Yao, Deng-Fu
    Yao, Min
    Huang, Hua
    Wu, Wei
    Yan, Mei-Juan
    Yan, Xiao-Di
    Chen, Jie
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (41) : 5897 - 5904
  • [6] Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma
    Zhang, Haijian
    Yao, Min
    Wu, Wei
    Qiu, Liwei
    Sai, Wenli
    Yang, Junling
    Zheng, Wenjie
    Huang, Jianfei
    Yao, Dengfu
    TUMOR BIOLOGY, 2015, 36 (12) : 9373 - 9383
  • [7] Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment
    Qiu, Li-Wei
    Liu, Yi-Fei
    Cao, Xiao-Qing
    Wang, Yan
    Cui, Xiao-Hong
    Ye, Xian
    Huang, Shuo-Wen
    Xie, Hong-Jun
    Zhang, Hai-Jian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (18) : 2126 - 2137
  • [8] Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma
    Mohammad, Hamdy Saad
    Kurokohchi, Kazutaka
    Yoneyama, Hirohito
    Tokuda, Masaaki
    Morishita, Asahiro
    Jian, Gong
    Shi, Liu
    Murota, Masayuki
    Tani, Joji
    Kato, Kiyohito
    Miyoshi, Hisaaki
    Deguchi, Akihiro
    Himoto, Takashi
    Usuki, Hisashi
    Wakabayashp, Hisao
    Izuishi, Kunihiko
    Suzuki, Yasuyuki
    Iwama, Hisakazu
    Deguchi, Kazushi
    Uchida, Naohito
    Sabet, Eman A.
    Arafa, Usama A.
    Hassan, Alit A.
    Masaki, Tsutomu
    El-Sayed, Adel A.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (06) : 1157 - 1163
  • [9] Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment
    Li-Wei Qiu
    Yi-Fei Liu
    Xiao-Qing Cao
    Yan Wang
    Xiao-Hong Cui
    Xian Ye
    Shuo-Wen Huang
    Hong-Jun Xie
    Hai-Jian Zhang
    World Journal of Gastroenterology, 2020, (18) : 2126 - 2137
  • [10] Annexin A2 as a differential diagnostic marker of hepatocellular tumors
    Longerich, Thomas
    Haller, Maria Theresia
    Mogler, Carolin
    Aulmann, Sebastian
    Lohmann, Volker
    Schirmacher, Peter
    Brand, Karsten
    PATHOLOGY RESEARCH AND PRACTICE, 2011, 207 (01) : 8 - 14